Metabolic carbonyl reduction of anthracyclines — role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents

Abstract

SummaryAnthracycline antibiotics (ANT), such as doxorubicin or daunorubicin, are a class of anticancer drugs that are widely used in oncology. Although highly effective in cancer therapy, their usefulness is greatly limited by their cardiotoxicity. Possible mechanisms of ANT cardiotoxicity include their conversion to secondary alcohol metabolites (i.e. doxorubicinol, daunorubicinol) catalyzed by carbonyl reductases (CBR) and aldo-keto reductases (AKR). These metabolites are suspected to be more cardiotoxic than their parent compounds. Moreover, overexpression of ANT-reducing enzymes (CBR and AKR) are found in many ANT-resistant cancers. The secondary metabolites show decreased cytotoxic properties and are more susceptible to ABC-mediated efflux than their parent compounds; thus, metabolite formation is considered one of the mechanisms of cancer resistance. Inhibitors of CBR and AKR were found to reduce the cardiotoxicity of ANT and the resistance of cancer cells, and therefore are being investigated as prospective cardioprotective and chemosensitizing drug candidates. In this review, the significance of a two-electron reduction of ANT, including daunorubicin, epirubicin, idarubicin, valrubicin, amrubicin, aclarubicin, and especially doxorubicin, is described with respect to toxicity and efficacy of therapy. Additionally, CBR and AKR inhibitors, including monoHER, curcumin, (−)-epigallocatechin gallate, resveratrol, berberine or pixantrone, and their modulating effect on the activity of ANT is characterized and discussed as potential mechanism of action for novel therapeutics in cancer treatment.

FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition

“…Doxorubicin (DOX) is a cytotoxic anthracycline antibiotic with susbtantial treatment potential in a broad variety of solid neoplasms ( 5 ). The major mechanism underlying the tumor-inhibiting activity of DOX is intercalation into primary double-stranded DNA, which blocks the interaction between DNA and RNA polymerases and results in impaired protein synthesis ( 6 ).…”

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors

“…For proteases similar to Mpro, the solute dielectric value that correlates best with experimental results is 4.0 (Sun et al, 2014). Three of the proposed drugs are used in chemotherapy (daunorubicin, amrubicin, and the valrubicin metabolite N-trifluoroacetyladriamycin) (Piska et al, 2017). These drugs as well as meclocycline, a highly toxic antibiotic, should be treated carefully because of side effects in the organism.…”

A Novel Platform Based on Au−CeO2@MWCNT Functionalized Glassy Carbon Microspheres for Voltammetric Sensing of Valrubicin as Bladder Anticancer Drug and its Interaction with DNA

“…Structurally, the lipophilicity properties of VLB are greater than that of doxorubicin which due to the presence of valerate moiety and the trifluoro-acetyl moiety on the amino group of the glycoside, resulting in enhanced intracytoplasmic concentrations [3]. VLB also produces two active metabolites (N-trifluoroacetyl-adriamycin, and Ntrifluoroacetyl-adriamycinol) which is its reduced form [4]. Nowadays, there is high cancer prevalence in modern societies and thus the scrutiny and monitoring of chemotherapy medicines are very important.…”